Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H8O8.Ca |
| Molecular Weight | 248.201 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].O[C@@H]([C@H](O)[C@@H](O)C([O-])=O)[C@H](O)C([O-])=O
InChI
InChIKey=UGZVNIRNPPEDHM-SBBOJQDXSA-L
InChI=1S/C6H10O8.Ca/c7-1(3(9)5(11)12)2(8)4(10)6(13)14;/h1-4,7-10H,(H,11,12)(H,13,14);/q;+2/p-2/t1-,2-,3-,4+;/m0./s1
| Molecular Formula | C6H8O8 |
| Molecular Weight | 208.1229 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Calcium-D-glucarate (also known as CALCIUM SACCHARATE) is the calcium salt of D-glucaric acid, a substance produced naturally in small amounts by mammals, including humans. Oral supplementation of calcium-D-glucarate has been shown to inhibit beta-glucuronidase, an enzyme produced by colonic microflora and involved in Phase II liver detoxification. Elevated beta-glucuronidase activity is associated with an increased risk for various cancers, particularly hormone-dependent cancers such as breast, prostate, and colon cancers. Other potential clinical applications of oral calcium-D-glucarate include regulation of estrogen metabolism and as a lipid-lowering. In addition, by reducing the beta-glucuronidase viability and activity of intestinal bacteria, salts of D-glucaric acid have been shown to enhance enterohepatic circulation and reduce steady state levels of cholesterol synthesis, resulting in decreased serum lipid levels.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2728 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2346674 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:18 GMT 2025
by
admin
on
Mon Mar 31 18:31:18 GMT 2025
|
| Record UNII |
SST07NLK7J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1108 (Number of products:5)
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
||
|
NCI_THESAURUS |
C1017
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
||
|
DSLD |
2385 (Number of products:29)
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
||
|
DSLD |
1681 (Number of products:125)
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
154911
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
5793-88-4
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
227-334-1
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
439
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
C84483
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
100000081613
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
SUB06056MIG
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
m2972
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
122011
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
1907
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID70227186
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY | |||
|
SST07NLK7J
Created by
admin on Mon Mar 31 18:31:18 GMT 2025 , Edited by admin on Mon Mar 31 18:31:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
SOLVATE->ANHYDROUS |
|